Plasmapheresis as a steroid saving procedure in bullous pemphigoid

International Journal of Dermatology

Volumn 39, Issue 3, 2000, Pages 230-235

  Egan, Conleth A ^a   Meadows, Kappa P ^b   Zone, John J ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTERONE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; TRIAMCINOLONE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DEMENTIA; DOSE RESPONSE; HEALTH CARE COST; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PEMPHIGOID; PLASMAPHERESIS; PNEUMOTHORAX; PROGNOSIS; SEPTICEMIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION; STEROID THERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; AUTOANTIGENS; AZATHIOPRINE; CARRIER PROTEINS; COLLAGEN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTOSKELETAL PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EVALUATION STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NON-FIBRILLAR COLLAGENS; PEMPHIGOID, BULLOUS; PLASMAPHERESIS; PREDNISONE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034001407     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.2000.00876.x     Document Type: Article

References (24)

1. Zillikens D, Giudice GJ, Diaz LA. Bullous pemphigoid. An autoimmune blistering disease of the elderly. J Geriatr Dermatol 1996; 4: 35-41.
2. Kelly SE, Wojnarowska F. The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid. Br J Dermatol 1988; 118: 31-40.
3. Sams WM Jr, Jordon RE. Correlation of pemphigoid and pemphigus antibody titres with activity of disease. Br J Dermatol 1971; 84: 7-13.
4. Stanley JR, Hawley-Nelson P, Yuspa SH, et al. Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell 1981; 24: 897-903.
5. Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol 1992; 99: 243-250.
6. Masunaga T, Shimizu H, Yee C, et al. The extracellular domain of BPAG2 localizes to anchoring filaments and its carboxyl terminus extends to the lamina densa of normal human epidermal basement membrane. J Invest Dermatol 1997; 109: 200-206.
7. Person JR, Rogers RS. Bullous and cicatricial pemphigoid. Clinical, histopathologic, and immunopathologic correlations. Mayo Clin Proc 1977; 52: 54-66.
8. Hadi SM, Barnetson RS, Gawkrodger DJ, et al. Clinical, histological and immunological studies in 50 patients with bullous pemphigoid. Dermatologica 1988; 176: 6-17.
9. Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy. Arch Dermatol 1977; 113: 1043-1046.
10. Roujeau JC, Revuz J, Touraine R, et al. Cortico-resistant bullous pemphigoid. Favorable results with plasmapheresis. Nouv Presse Med 1979; 8: 3362.
11. Goldberg NS, Robinson JK, Roenigk HH Jr, et al. Plasmapheresis therapy for bullous pemphigoid. Arch Dermatol 1985; 121: 1484-1485.
12. Konstadt JW, Remlinger K, Schild J, et al. Refractory bullous pemphigoid leading to respiratory arrest and successfully treated with plasmapheresis. Arch Dermatol 1990; 126: 1241-1242.
13. Roujeau JC, Guillaume JC, Morel P, et al. Plasma exchange in bullous pemphigoid. Lancet 1984; 2: 486-488.
14. Zone JJ, Taylor TB, Kadunce DP, Meyer LJ. Identification of the cutaneous basement membrane zone antigen and isolation of antibody in linear immunoglobulin A bullous dermatosis. J Clin Invest 1990; 85: 812-820.
15. Meyer LJ, Taylor TB, Kadunce DP, et al. Bullous pemphigoid antigens: extraction and degradation of antigens during epidermal preparation. J Invest Dermatol 1991; 96: 991-993.
16. 4. Nature 1970; 227: 680-685.
17. Towbin HT, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4354.
18. Liu Z, Diaz LA, Troy JL, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993; 92: 2480-2488.
19. 95 with human intravenous immunoglobulin. Sci 1998; 282: 490-493.
20. Godard W, Roujeau JC, Guillot B, et al. Bullous pemphigoid and intravenous gammaglobulin. Ann Intern Med 1985; 103: 964-965.
21. Beckers RC, Brand A, Vermeer BJ, et al. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br J Dermatol 1995; 133: 289-293.
22. Tappeiner G, Steiner A. High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid. J Am Acad Dermatol 1989; 20: 684-685.
23. Jolles S, Hughes J, Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 1998; 134: 80-86.
24. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227-228.